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Abstract 
The p53 tumor suppressor protein is involved in multiple central cellular 
processes and human cancer occurrences. A research effort is proposed to collect the 
majority of p53 ChIP fragments up to now and reveal the binding pattern of p53 
binding sites. It demonstrates that the normal and cancer cell lines have significantly 
different chromatin organizations around P53 binding sites. Based on the high 
occurrences, the core binding sites can be collected to analyze gene expression 
configurations. Depending on the accessibility of p53 sites and epigenetic marks in 
the chromatin context, p53 binds to its target sites in repetitive regions. Finally, the 
functional annotation analysis illustrates that the most enriched pathway of p53 ChIP 
fragments is p53 signaling pathway and highly enriched clusters relating to apoptosis, 
DNA damage and cellular signaling are modulated by p53.  
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Introduction 
Biological Background 
The human genome contains approximately 3 billion base pairs of DNA 
packaged into 23 chromosomes. Each cell has two copies of genetic information. 
There are about 50 trillion cells, tens of thousands of individual proteins and genes, in 
typical human body. The Central Dogma of Molecular Biology reveals the genetic 
inheritance and specification: replication of DNA, transcription into mRNA and 
translation into protein.  
The large amount of genetic information is arranged into a structure called 
chromatin. Chromatin is composed of a combination of DNA, histones and certain 
types of RNA. The basic, repeated structure unit of chromatin is the nucleosome. 
Histones are alkaline, positively charged proteins, which include 4 core histones, 
namely H2A, H2B, H3, and H4. H2A and H2B residing in core domain keep from 
organize to nucleosomes. H3 and H4 locating in the side of the structure bind to the 
DNA to regulate chromatin formation [1]. H1 and H5 are the linker histones. They 
bind with nucleosome core and linker DNA [2]. A strand of 145bp DNA wraps in 1.6 
turns around the core histones (Figure 1) [3].  
 
Figure 1. Nucleosomal DNA wraps around histones 
 
 
The ability of interaction between Transcriptional Factors (TFs) and their cognate 
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sites will be weakened, given the DNA sequence occluded by nucleosomes. Two 
main factors have been identified to be able to regulate the function state of chromatin. 
One is the methylated DNA and the other is modified histone protein [4]. While the 
DNA methylation can be found in most CpGs area of the genome [5], the histone 
modification occurs more widely within the amino-terminal histone tails relating with 
various biological functions.  
A protein should contact with histones or nucleosomal DNA to interact with a 
nucleosome. The target sites cannot access protein successfully if its nucleosome is 
wrapped tightly. Several researchers show that some specific proteins can bind to 
DNA sequences directly (hereafter “nucleosome DNA-binding proteins”) in vitro and 
in vivo, such as telomeric protein Rap1p [6], yeast chromatin-remodeling complexes 
SWI/SNF, RSC [7] and so on. The modification of Nucleosome-Interacting Proteins 
can influence the DNA binding to TFs. 
 
DNA Binding Protein - P53 
In this study, we focus on the best-known tumor suppressor protein p53, which 
works as a sequence-specific transcription factor. P53 with a high-resolution crystal 
structures plays an important role in various central cellular processes, such as the 
maintenance of genetic stability, cell cycle control, transcription, DNA repair, 
apoptosis and other responses [8]. In most cases of human cancers, p53 mutates is 
functionally inactivated by signal-dependent modifications, since the central 
conserved region of p53 is necessary and important for specific DNA binding [9]. 
When the cell is normal and unstressed, the short-lived p53 protein level can keep a 
low turnover and latent state. However when p53 is activated due to some genotoxic 
stresses like DNA damage, nucleotide depletion and hypoxia, p53 will accumulate 
and work as a transcription factor. The activation can inhibit many gene expressions 
and induce some responses like cell cycle arrest or apoptosis [10].  
Kaeser and Lggo [11] proposed some models to explain why p53 causes cell 
cycle arrest in some places and apoptosis in others. The reason is that p53 binds with 
high affinity to the response elements regulating cell cycle arrest genes (CCA-sites) 
	 9	
and binds to the promoters of apoptosis (Apo-sites) – inducing genes with a lower 
affinity. The evidence is that some low-affinity mutants keep the ability to induce cell 
cycle arrest.  
 
The Structure of P53 
The DNA-binding protein P53 looks like a self-assembled tetramer [11]. It 
contains two copies of a decamer motif "RRRCWWGYYY"(R=A, G; W=A, T; Y=C, 
T) separated by a variable spacer of 0 to 13 base pairs (Figure 2).  
 
Figure 2. Four p53 core domains bound to bent DNA. 
                
                  
P53 has four molecules of DNA binding domain (p53DBD) [12]. More than 80% 
missense mutations happen in p53DBD, which leads to DNA binding disrupture or 
stability reduction [11]. These four p53 motifs are positioned on the external side of 
the DNA loop and recognize their cognate sites in nucleosome DNA if the p53 sites 
are exposed (Figure 2). P53DBD bends the DNA to improve the stability and 
cooperation of binding.  
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Figure 3. Modeling of p53 tetramer bound to nucleosome DNA. 
              
 
Sahu and Wang [13] reported the idea that when the p53 binding sites are bent in 
the same direction with DNA complexes in solution and in co-crystals, the sites have 
high accessibility. However, if the direction of p53 binding sites in the core particle 
are turned ~ 180 degrees, they become inaccessible. That means they are in the 
opposite directions and statuses. Figure 3 shows that when the p53 binding sites are 
exposed on the nucleosome surface, they are recognized by corresponding p53. 
Therefore, the direction and position of the p53 binding sites determine whether or 
not they can be contacted easily. When the p53 site is “exposed” to the surface, it is 
accessible to p53. By contrary, it is inaccessible if the site is “buried”.  
 
Thesis Goals 
 In this study, we collected the most comprehensive p53 ChIP fragments to 
compare the normal and cancer cell lines. Clusters with overlapping p53 ChIP 
fragments will be analyzed in terms of their distances to the transcription start site 
(TSS) of nearest genes. We hypothesize that there is a significant difference in the 
distances between the normal and cancer p53 clusters. Using statistic analyses, we can 
test this hypothesis.  
Some researchers reported that various p53 binding sites have been identified in 
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sequences of primate-specific interspersed repeats. Around 1509 of ≈319, 000 human 
ERV LTR regions have a near-perfect p53 DNA binding site [14]. Zemojtel et al. [15] 
reported that about 15 percentages of in vivo p53 sites could be derived in the short 
interspersed nuclear element (SINE). Harris et al. [16] also detected that a large 
number of p53 DNA binding sites in long interspersed nuclear elements-1 (L1s) 
within the human genome. All these p53 binding sites reside in the 19 
primate-specific Alu elements (SINE). Therefore, we plan to detect all the p53 
binding sites up to now residing in repetitive regions and investigate their 
distributions. The Gudkov’s group has shown that p53 cooperates with DNA 
methylation to maintain epigenetic silencing of repeats, which include major classes 
of short, interspersed nuclear elements (SINE) B1 and B2 [17]. Thus we will analyze 
all the collection of p53 ChIP fragments to see how they are distributed among 
repetitive regions. Furthermore, based on the observations of these clusters, we can 
reveal their highly enriched pathways and clusters to do p53 functional analysis.  
 
Methods and Materials 
Collection of P53 Binding Sites 
Generally, there are two main different ways to identify p53 binding sites (BSs). 
The first traditional approach [18] focuses on a specific p53 response element (RE), 
which can be regulated by p53 protein. It demonstrates the p53 RE by test gene 
regulation and chromatin immunoprecipitation with a p53-specific antibody. The 
second approach is high-throughput sequencing of chromatin immunoprecipitated 
DNA (ChIP-seq), which can map the in vivo genome-wide binding sites of 
DNA-binding proteins [19]. The extractions of the p53-bound DNA fragments by 
chromatin immunoprecipitation (ChIP) are denoted ChIP fragments below.  
For better analysis, we translated all the p53 ChIP fragments into the same 
assembly hg18 by UCSC genome browser liftOver utility 
(https://genome.ucsc.edu/cgi-bin/hgLiftOver). Based on the cell type, they were 
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separated into two datasets: cancer p53 ChIP fragments and normal p53 ChIP 
fragments. 
 
Concordance Between P53 Binding Sites Identified in Vitro and in Vivo 
Besides the collected ChIP segments identified in vivo, a list of known 154 
famous p53 REs [18] were studies to validate the assumption that the p53 ChIP 
fragments can show the strong evidence of REs. Riley et al. [18] proposed that to 
identify p53 – regulated genes, several criteria should be executed. P53 REs near or in 
the gene could regulate the test gene and be regulated by activated wild p53 protein. 
Most REs contains two half sequencing sites separated by a variable length spacer.  
Once the ChIP fragments and REs are prepared, the sequence data and 
annotations can be visualized using UCSC Genome Browser 
(https://genome.ucsc.edu). Import the normal datasets and cancer datasets as 
annotations tracks with assembly hg18 in Genome Brower. Then locate the p53 REs 
in UCSC Genome Browser based on their genome positions to focus on the specific 
areas. Therefore, we can have an overview of the p53 REs distributions in p53 ChIP 
fragments.  
 
Detection of P53 Core Binding Sites 
Many binding sites were shared by most of the experiments/treatments, like 5-FU, 
Nutlin 3a. After mapping all the p53 binding sites to the human genome (hg18), there 
are many overlapping areas in every human chromosome. So along the chromosome, 
every fragment has the occurrence based on its position. If we make a curve of the 
occurrences along the chromosome, multiple peaks can be identified indicating the 
high frequencies of certain binding sites. We can set cut-off values for the core 
binding sites. Thus collect those sites with high occurrence numbers larger than cut 
off value as the core binding sites. From UCSC table browser 
(https://genome.ucsc.edu/cgi-bin/hgTables), we are able to get human RefSeq gene 
information. The locations of these core binding sites with human RefSeq files were 
compared with the midpoint of the fragments, such that the closest gene for each core 
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binding sites can be identified. These genes will be used for further functional 
annotation studies.  
 
Distance Distribution of P53 Binding Sites 
The chromatin context provides another perspective to see the regulation of 
p53-DNA binding. Many studies were revealed that p53 genomic binding patterns in 
normal cell lines is distinct from that in cancer cell lines, which means that the 
chromatin organizations around p53 binding sites are different between normal cells 
and cancer cells. It can help us understand the role of cell context, experimental 
conditions in p53 binding, mutation factors and influence of chromatin states on 
modulation of p53-DNA binding. Based on the collection of p53 binding sites 
mapped in normal cell lines and cancer lines, a statistic analyses on the distances to 
the transcription start sites (TSSs) of nearby genes was conducted. Different 
distribution situations were compared between these two sets of p53 binding sites. To 
test the hypothesis that there is significant difference between normal and cancer cell 
lines in chromatin distribution, we calculate the means and p-value of these two 
groups.  
 
P53 Binding Sites Residing in Repeats 
Many of the p53 binding sites (normal or cancer) are found locating in 
transposable repetitive regions in the human genome. Wei et al. [20] reported that 
over 30% of p53 sites are highly enriched in human ERV LTR regions. They 
collected only hundreds of p53 cancer binding sites. We collected much more p53 
ChIP fragments including their dataset to get a more comprehensive result. Also it’s 
important to compare the different repetitive distribution between normal and cancer 
cell lines. From the UCSC genome annotation database, we can get the human hg18 
genome annotation files for each chromosome with the repeat regions. Then map the 
normal p53 BSs and cancer p53 BSs to the repeat regions based on their chromosome 
positions. We are able to get the number of repeat classes and repeat families in 
normal as well as cancer p53 BSs respectively and calculate the percentages of every 
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kind of repeats. Therefore we have a complete set of p53 binding sites residing in 
repetitive regions. 
 
Functional Annotation of P53 ChIP Clusters 
Large amount of p53 fragments are widely distributed in human genome and p53 
tumor suppressor pathways have a high correlation with growth-inhibitory activity of 
123 anticancer agents in more than 60 cell lines [21]. The single-nucleotide 
polymorphisms (SNPs) in the p53-pathway have apparent influence on the alteration 
of its function [22]. Several studies reported about the signaling pathways enriched in 
HCT116 [23] and IMR90 [24] by using the genes harboring p53 binding sites. They 
found the common pathway is p53 signaling pathway. But the most highly enriched 
pathways in HCT116 and IMR90 are different. Smeek et al. [25] also performed 
functional annotation for p53 phosphorylated at S46 and found that p53 signaling 
pathway is the most enriched cluster. The next two important functional categories are 
nuclear envelope and cell cycle regulation. So it is meaningful to analyze p53 
pathways and function annotation.  
DAVID (the Database for Annotation, Visualization and Integrated Discovery) is 
a bioinformatics resource used for functional interpretation of large lists of genes or 
proteins [26, 27]. So we can import the genes list of p53 ChIP clusters to DAVID to 
get their pathways. The DAVID Functional Annotation Clustering Tool also measures 
the relationships of annotation terms and show cluster groups [28]. We can compare 
the pathways and clusters differences between cancer and normal cell.  
Results 
Collection of P53 Binding Sites and Lengh-distribution 
After searching and studying most published articles relating to p53 binding sites 
in vivo and in vitro, we have collected 154 p53 REs (Appendix Table A-1) and about 
120,000 identified ChIP fragments from 25 datasets (Table 1). These ChIP segments 
are classified into 9 normal datasets and 16 cancer datasets according to cell type 
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under different treatments.  
 
Cell 
type 
Cell 
line 
Treatment 
Exp. 
technique 
Binding 
sites 
Reference 
Botcheva 
(2011) 
normal IMR90 5-FU ChIP-seq 743 24 
Zeron-Medina 
(2013) 
normal 
lympho
blastoid 
Nutlin 3a 
ChIP-seq 
1,084 
29 DXR 12,792 
IR 152 
Akdemir 
(2014) 
normal hESC 
DXR (Adr) 
ChIP-seq 
4,324 
30 
RA (re) 7,197 
McDade 
(2014) 
normal 
keratin
octye 
DXR(Adr) 
ChIP-seq 
4,169 
31 
cisplatin 8,629 
Su (2015) normal 
lympho
blastoid 
DXR ChIP-seq 2,930 32 
Wei (2006) cancer HCT11
6 
5-FU ChIP-PET 542 20 
Smeenk (2008) cancer U2OS Actinomycin D ChIP-chip 1,545 33 
Smeenk (2011) 
cancer 
 
U2OS 
 
Etoposide 
ChIP-seq 
2,920 
25 
Actinomycin D 2,132 
Nikulenkov 
(2012) 
cancer MCF7 
Nutlin 3a 
ChIP-seq 
16,707 
34 RITA 10,622 
5-FU 10,365 
Menendez cancer U2OS Nutlin 3a ChIP-seq 18,158 35 
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(2013) DXR 3,087 
Botcheva 
(2014) 
cancer 
HCT11
6 
5-FU ChIP-seq 550 23 
Rashi-Elkeles 
(2014) 
cancer CAL51 IR ChIP-seq 1,825 36 
Sanchez (2014) cancer 
HCT11
6 
5-FU ChIP-seq 3,668 37 
Chang (2014) cancer U2OS 
Nutlin 3a 
ChIP-exo 
952 
38 
5-FU 1864 
DXR 1303 
UV 1556 
Table 1. Summary of p53 binding sites in vivo identified by ChIP experiments 
After collecting all the p53 binding sites in Table 1, we separated them into 
normal cell lines and cancer cell lines separately. There are 77,796 p53 binding sites 
in cancer cell lines and 42,020 in normal cell lines. 
 
Figure 4. Length - frequency distributions of ChIP segments. 
A                                 B 
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C 
 
 
D 
 
 
 (A) Total 42020 normal segments length – frequency distribution. (B) Total 77796 
cancer segments length – frequency distribution. (C) 9 normal datasets length – 
frequency distribution. (D) 16 cancer datasets length – frequency distribution. 
 
Based on the start and end position of ChIP segments, the length distribution is 
firstly analyzed. The normal (Figure 4A) cell lines provide a wider length distribution 
than cancer (Figure 4B) cell lines. The lengths of p53 binding sites in cancer 
concentrate mainly on 0~500bp. While for normal cell lines, the lengths cover from 
0~2000bp. It shows that cancer segments are much shorter than normal segments on 
average. The peak value of normal cell lines is around 1000pb while it is 500pb in 
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cancer cell lines. From every dataset length distribution, normal ChIP fragments are 
longer than cancer on average. We need to investigate the reasons for this difference 
in the future.  
 
Concordance Between P53 Binding Sites Identified in Vitro and in Vivo 
Based on work of Riley et al. [18], we collected 154 famous p53 REs (Appendix 
Table A-1). In the research of Riley et al. [14], they have 156 binding sites. We 
remove the human hepatitis B virus (HBV) site and one overlapping CDKN1A (p21) 
sites.  
To study the correlation between p53 binding sites identified in vitro and in vivo, 
we imported all ChIP segments to UCSC Genome Browser to do visualization. Then 
mapped the targeted 154 REs based on their chromosomes and positions (Appendix 
Table A-1). All the custom track figures of p53 REs can be checked in Supplementary 
Figure S1. 
We can find that 71 out of 154 (46%) REs overlap with ChIP fragments. So it is 
obvious that the ChIP segments can cover the most of targeted genes. 
 
Figure 5. BBC3 (PUMA) gene in UCSC Genome Browser 
 
A (normal) 
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B (cancer) 
 
Figure 5 shows one main famous target gene BBC3 (PUMA) overlaps with ChIP 
fragments locating in normal and cancer cell line separately through the UCSC 
Genome Browser. It concluded that the p53 binding sites identified in vitro has a very 
high concordance with those identified in vivo. Based on the figures, besides the 
targeted genes position, there are many other areas that are covered by many ChIP 
segments from different datasets. For example, the black arrows in Figure 5 point the 
common areas. It may help to better identify p53 binding sites relating these areas in 
the future.  
 
Detection of P53 Core Binding Sites 
Many p53 ChIP fragments have overlapping positions in the human genome 
(hg18), so we collected those sites with high occurrence numbers as the core set. 
After mapping all normal and cancer fragments to human genome (hg18) based on 
their chromosome positions, we found that 44% (18,565 out of 42,020) normal 
fragments are singletons and 40% (31,212 out of 77,796) cancer fragments are 
singletons. They do not overlap with other p53 binding sites. The other fragments 
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overlap with each other to be clusters. Based on there number of overlapping times, 
we denoted them as pile-2, pile-3, pile-4 and so on. For p53 normal fragments, the 
percentage of pile2 is 11% and pile 3 is 0.5%. P53 cancer cells have the similar 
percentage trend with normal cells. So we set the cut-off value of 3 to be core binding 
sites. That means that the fragments with occurrences equal or larger than 3 are core 
binding sites. We denoted them as “pile-3+”. According to statistics, the normal 
pile-3+ containing 3551 fragments (Supplementary Table S1). While cancer pile-3+ 
has 6039 fragments (Supplementary Table S2).  
 
Figure 6. Overlapping fragments between cancer clusters and normal clusters 
              
              Normal           Cancer 
  
After comparing normal pile-3+ and cancer pile-3+, we found the Figure 7 
overlapping results. Normal pile-3+ has 2157 fragments overlapping with cancer 
pile-3+ while cancer pile-3+ only has 2320. The reason is that the average normal 
fragments are longer than cancer fragments as we mentioned in previous 
length-frequency distribution analysis. So one fragment in normal cells may overlap 
more than one cancer fragment. For better description, we denote the p53 ChIP 
fragments that only belong to normal or cancer cells as “normal_only” group or 
“cancer_only” group. Also we name the overlapping fragments as “normal/cancer” 
group.   
 
Distance Distribution of P53 Binding Sites 
From UCSC Table Browser we downloaded human RefSeq Genes table with 
assembly hg18. Then mapped the normal and cancer pile-3+ fragments 
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(Supplementary Table S1, S2) to this table based on their positions to find nearest 
RefSeq genes. If the ChIP fragment is upstream to the transcription start site (TSS) of 
a give gene, the distance is ‘-‘. Otherwise the distance has a ‘+’ sign. The RefSeq 
gene names and distances are added to the pile-3+ table with column names “Gene 
Name” and “Peak to TSS” (Supplementary Table S1, S2).  
 
Figure 7. Genomic distributions of pile-3+ binding sites (BSs) to TSSs 
  
                    A. Normal                    B. Cancer 
 
After a statistics analysis of the lengths from p53 binding sites to the 
transcriptional start sites (TSSs) in normal and cancer cell lines, it showed significant 
differences between the two cases in Figure 6. In cancer BSs the proportion of “>25kb” 
is much higher than normal. While the part “<1kb” is smaller in cancer than normal. 
On the whole, cancer p53 BSs are located far from TSSs and normal BSs are near the 
TSSs. This shows that they have the apparently different genomic distributions and 
chromatin context. We used the absolute distance values for hypothesis test and got 
the average distance 66389.03 for normal cell lines and 74972.97 for cancer cell lines. 
The p-value got from T-test is 0.00165, which is much smaller than 0.05. It 
demonstrates that there is significant difference in the distances between normal and 
cancer p53 clusters.  
 
P53 Binding Sites Residing in Repeats 
 After mapping pile-3+ normal and cancer ChIP fragments (Supplementary Table 
S1, S2) to human genome annotation table based on their positions. We got repeated 
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name, repeated class and repeated family information for normal_only, cancer_only 
and normal/cancer groups and conducted a statistical analyses (Table 2). The repeated 
types include SINE (MIR, Alu), Simple Repeat, LTR, Low Complexity, LINE (CR1, 
L1, L2, RTE), DNA. The remaining repeated types with lower occurrences were 
added up to be “Other” category.  
 If the ChIP fragments are not in any repeat areas, they are classified as 
“Not_in_repeat” category. If the ChIP fragments cover more than one repeat area, all 
the repeat categories are counted.   
A: 
  Normal Normal/Cancer Cancer 
All repeat types Count Percentage Count Percentage Count Percentage 
SINE 1382 39.09% 1260 28.42% 1568 26.79% 
Simple_repeat 342 9.67% 334 7.53% 323 5.52% 
Other 45 1.27% 21 0.47% 69 1.18% 
Not_in_repeat 166 4.70% 479 10.81% 1268 21.66% 
LTR 455 12.87% 1046 23.60% 843 14.40% 
Low_complexity 332 9.39% 213 4.80% 259 4.43% 
LINE 618 17.48% 827 18.66% 1139 19.46% 
DNA 195 5.52% 253 5.71% 384 6.56% 
Total 3535 100.00% 4433 100.00% 5853 100.00% 
 
B: 
  Normal Normal/Cancer Cancer 
SINE Count Percentage Count Percentage Count Percentage 
MIR 526 38.06% 461 36.59% 570 36.35% 
Alu 856 61.94% 799 63.41% 998 63.65% 
Total 25 4.05% 1260 100.00% 50 4.39% 
 
C: 
  Normal Normal/Cancer Cancer 
LINE Count Percentage Count Percentage Count Percentage 
CR1 25 4.05% 41 4.96% 50 4.39% 
L1 305 49.35% 488 59.01% 616 54.08% 
L2 280 45.31% 285 34.46% 462 40.56% 
RTE 8 1.29% 13 1.57% 11 0.97% 
Total 618 100.00% 827 100.00% 1139 100.00% 
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D: 
  Normal Normal/Cancer Cancer 
Alu Count Percentage Count Percentage Count Percentage 
AluJb 111 12.97% 133 16.65% 153 15.33% 
AluJo 125 14.60% 147 18.40% 150 15.03% 
AluSc 25 2.92% 27 3.38% 32 3.21% 
AluSg 64 7.48% 40 5.01% 69 6.91% 
AluSg/x 14 1.64% 23 2.88% 32 3.21% 
AluSp 45 5.26% 30 3.75% 35 3.51% 
AluSq 68 7.94% 51 6.38% 70 7.01% 
AluSx 247 28.86% 227 28.41% 256 25.65% 
AluY 79 9.23% 42 5.26% 88 8.82% 
FLAM_A 12 1.40% 8 1.00% 19 1.90% 
FLAM_C 20 2.34% 24 3.00% 31 3.11% 
FRAM 15 1.75% 18 2.25% 30 3.01% 
Other 31 3.62% 29 3.63% 33 3.31% 
Total 856 100.00% 799 100.00% 998 100.00% 
Table 2: The statistics results of p53 ChIP fragments in repetitive regions. Statistics 
are shown for (A) All repeat types; (B) Short interspersed nuclear elements (SINE); 
(C) Long interspersed nuclear elements (LINE); (D) Alu elements. 
 
Here we focused on their distributions in all repeat types, short interspersed 
nuclear elements (SINE), long interspersed nuclear elements (LINE) and Alu 
elements. Based on percentages of various repeat categories, the pie charts are shown 
for better display (Figure 8).  
 
Figure 8. Pie charts of p53 clusters residing in repeat regions 
 
A                       B                       C 
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D                         E                         F          
 
       G                          H                         I 
    
J                           K                         L 
 (A) All repeat types for normal_only group. (B) All repeat types for normal/cancer 
group. (C) All repeat types for cancer_only group. (D) Short interspersed nuclear 
elements (SINE) for normal_only group. (E) Long interspersed nuclear elements 
(LINE) for normal_only group. (F) Alu elements for normal_only group. (G) Short 
interspersed nuclear elements (SINE) for normal/cancer group. (H) Long interspersed 
nuclear elements (LINE) for normal/cancer group. (I) Alu elements for normal/cancer 
group. (J) Short interspersed nuclear elements (SINE) for cancer_only group. (K) 
Long interspersed nuclear elements (LINE) for cancer_only group. (L) Alu elements 
for cancer_only group. 
 
Based on the statistic results (Table 2) and pie charts (Figure 8), we can find that 
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normal cells have a big difference in the distribution of repetitive regions compared 
with cancer cells. For p53 binding sites in normal_only group, highest proportion 
“SINE” category reaches 39%. While in normal/cancer and cancer_only group, 
“SINE” only has 26% and 28%. The biggest difference is the sites that are not in any 
repetitive regions. In normal_only group, “Not_in_repeat” is only 4.7%. But in 
cancer_only group there are 10% of ChIP fragments that are not in any repetitive 
regions. The percentage of “LTR” in normal/cancer group is much higher than 
normal_only and cancer_only groups. It reaches 23%, which demonstrates the 
conclusion that one-third of p53 binding sites containing LTRs [14]. 
In the repeated family “SINE” (Figure 8D, Figure 8G, Figure 8J), “LINE” 
(Figure 8E, Figure 8H, Figure 8K) and “Alu” elements (Figure 8F, Figure 8I, Figure 
8L), there are no evidential differences among cancer_only, normal/cancer and 
normal_only groups. In the “SINE” repeat family, “Alu” can reach to about 60% in 
all of them.  
 
Functional Annotation of P53 ChIP Clusters 
In Figure 6, most of the p53 ChIP clusters are located far away from TSSs (>10 
kb). Thus the genes of p53 binding sites with the distances 5kb upstream/downstream 
of transcription start sites (TSSs) were selected as our targeted genes. We have got the 
genes list of p53 ChIP fragments in previous “Distance Distribution” step. So we 
imported gene lists of normal_only, normal/cancer and cancer_only groups to DAVID 
(https://david.ncifcrf.gov/). From DAVID Pathway Viewer, obviously we can find 
Kyoto Encyclopedia of Genes and Genomes (KEGG) database containing genes from 
list. The following Figure 9 shows the significant KEGG pathways of normal_only, 
normal/cancer and cancer_only groups. We chose the pathways with statistical 
significant p-value < 0.01.  
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Figure 9. Enriched pathways for p53 genes from DAVID 
A  
B  
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C  
Most highly enriched KEGG pathway in DAVID functional annotation analysis of the 
genes associated with p53 ChIP fragments (p-value <0.01). Fold enrichment is 
calculated by DAVID. (A) Normal_only group. (B) Normal/cancer group. (C) 
Cancer_only group. 
 
Figure 9A, 9B, 9C show the enriched KEGG pathways for normal_only, 
normal/cancer and cancer_only groups. P53 signaling pathway in both normal/cancer 
and cancer_only group has the highest fold enrichment values 9.6 and 4.4. In 
normal/cancer group, three other groups are also showed, “bladder cancer”, 
“apoptosis” and “phosphatidylinositol signaling system”. The changes in the 
molecules in the p53 genes and pathways can regulate the cell cycle and affect 
bladder cancer [39]. Haupt et al. [40] reported that p53 activates signals through two 
major apoptotic pathways: the extrinsic, death receptor pathway and the intrinsic, 
mitochondrial pathway. The tumor suppressor PTEN antagonizing 
phosphatidylinositol-3,4,5-trisphosphate (PIP3) regulates p53 pathway [41]. These 
prove that the pathways from our p53 ChIP fragments are involved in the p53 
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transcriptional programs.  
 
Figure 10. Enriched clusters for p53 genes from DAVID 
A  
B  
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Figure 10: Most highly enriched clusters in DAVID functional annotation analysis of 
the genes associated with p53 ChIP fragment. See Supplementary Table S8-S9 for all 
enriched clusters. (A) Normal_only group. (B) Normal/cancer group. (C) 
Cancer_only group. 
 
Figure 10A, 10B, 10C show the highly enriched clusters of genes for 
normal_only, normal/cancer and cancer-only groups. They are arranged based on the 
enrichment scores. From normal/cancer groups (Figure 10B), we can find that the 
most significant GO terms include ‘‘Regulation of apoptosis’’, “DNA damage 
response” and “Cellular response to stress”. These demonstrate that the p53 clusters 
from p53 ChIP fragments are bound up with genes relating with cell cycle control and 
apoptosis.  
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Discussion 
Chromatin Context and Distribution 
P53 plays an important role in regulating cell cycles and maintaining genomic 
stability. The transcription regulation can be influenced by many factors. Leroy et al. 
[42] reported that more than half of human cancers carry TP53 gene mutations and 
these relate with p53 REs. Posttranslational Modification can impact the p53 function 
in response to genotoxic or nongenotoxic stresses [43]. Some family members like 
p63 and p73 can also influence p53 activities [44]. All these factors active in the p53 
chromatin context because p53 plays a role in transcription regulation and interactions 
with DNA. In this study, different p53 chromosome distributions and organizations 
between normal and cancer cell lines were analyzed using ~120,000 ChIP fragments.  
As our datasets are comprehensive and cover most published p53 DNA binding 
sites in vivo, the normal and cancer cell lines are under the same treatments (Table 1). 
For example, both of them have treatments like 5-FU, Nutlin 3a, DXR. Actually these 
datasets come from different experiments, labs and researches. From our results in 
“Concordance between P53 Binding Sites and ChIP Fragments” and “Core Binding 
Sites”, there were consistently large overlapping areas. So the chromatin context 
analyses in our research has statistic significance.  
 
P53 Distributions in Repetitive Regions in Normal and Cancer Chromatin 
The majority of p53 binding sites locate in many repetitive regions: SINE, LINE, 
Alu and so on. Cui et al. [45] proposed that the primate-specific Alu repeats involve 
in changing the p53 regulatory network in the chromatin context. In this study, we 
focus on the different repetitive distributions between normal and cancer cell lines 
relating with chromatin context. For example, cancer_only group has a much larger 
“Not_in_repeat” percentage than normal_only group. This may result from their 
different chromatin organization. Many factors probably influence this different 
distribution, like the p53 binding activity, DNA hypomethylation in cancer cells.  
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Future Work 
This study is focused on p53 binding sites configuration. The differences of 
chromatin context and distribution between cancer cell lines and normal cell lines 
have been analyzed from several aspects, such as length distributions of p53 binding 
sites, overlapping areas, distribution of various repeat categories and enriched 
pathways and clusters. Additional research and work can be investigated based on this 
p53 dataset.  
From the visualization results of these ~120,000 ChIP fragments, we can find that 
it covers about 46% of the 154 REs list. There still have 54% percentages of REs are 
not included. Also from Table 1, the normal and cancer cell lines were found to share 
many several treatments. But some treatments just belong to one cell type. For 
example, normal ChIP fragments have cisplain treatment while cancer does not have. 
These mean our dataset still needs supplement in the future, which can provide more 
instructive results.  
Millau et al. [46] reported that the chromatin is the reason for the formation of 
stress-specific p53 binding patterns. The sequence-specific p53 binding affinity 
cannot change the p53 binding patterns. While some treatments, like UVB, Nutlin-3, 
can get different cellular results. In our research, we collected large number of p53 
ChIP fragments to form a distinct p53 binding patterns consisting of normal and 
cancer cell lines. Further analysis can be carried out on our p53 binding patterns with 
stress treatments. We can see how p53 has specific gene regulation in response to 
stress in normal and cancer cell lines.  
 
Conclusions 
This thesis research involved many public ChIP data to do p53 chromatin context 
study. All the largest amount of data were analyzed by computer language R and 
performed on the public bioinformatics platform, like UCSC, DAVID. The 
comparison of chromatin organization and distribution between normal cell lines and 
cancer cell lines can help us have more pertinent and specific research in the future. 
From our statistic results, we tested the hypothesis and demonstrate that normal can 
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cancer cell lines have different chromatin distribution. We also reveal the enriched 
pathways and clusters to demonstrate p53 transcriptional function, which represents 
the direction and emphasis for future analysis.  
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Appendix A 
Name Chr Strand Start End 1st half-site Spacer 2nd half-site 
Overlap 
with 
ChIP? 
ABCB1 7 ― 87068176 87068208 GGGCAGGAAC agcgccggggcgt GGGCTGAGCA No 
ACTA2 10 ― 90702802 90702821 AACCATGCCT   GCATCTGCCC No 
AIFM2_RE1 10 ― 71563263 71563292 AGGCATGAGC caccgtgcct GGCCATGCCC No 
AIFM2_RE2 10 ― 71563350 71563377 GGTCTCGCTA tgttgccc AGGCTGGTCT No 
ANLN 7 + 36395090 36395115 GAACTGGCTT  ttctga  GGGCCAGGCC No 
APAF1 12 + 97562605 97562637 AGACATGTCT ggagaccctagga CGACAAGCCC Yes 
APC 5 + 112101252 112101283 GGGCATACCC ccgaggggtacg GGGCTAGGGC No 
ARID3A 19 + 884568 884587 GGACACGCTG   GGACATGCCT Yes 
ATF3 1 + 210848347 210848383 AGTCATGCCG ctggcttgggcaccatt GGTCATGCCT Yes 
BAI1 8 + 143559821 143559840 GTGGCTGCCT   GGACATGTTC Yes 
BAX 19 + 54150282 54150301 GGGCAGGCCC   GGGCTTGTCG Yes 
BBC3 19 ― 52426417 52426436 CTGCAAGTCC   TGACTTGTCC Yes 
BCL2L14 12 + 12117280 12117299 AGCCAAGGCT   GGTCTTGAAC No 
BCL6 3 ― 188945441 188945472 GACAGTGCTT ggggggtgattc GGGCTAGTCT No 
BDKRB2 14 + 95740864 95740883 GGAagTGCCC   AGGaggcTga Yes 
BID 22 ― 16619483 16619502 GGGCATGATG   GTGCATGCCT No 
BIRC5 17 + 73721905 73721927 GGGCGTGCGC tcc CGACATGCCC No 
BNIP3L 8 + 26331013 26331037 AAGCTAGTCT cagtg GcGCATGCCT No 
BTG2 1 + 201541261 201541280 AGTCCGGGCA   GAGCCCGAGC Yes 
C12orf5 12 + 4301042 4301063 AGACATGTCC ac AGACTTGTCT Yes 
C13orf15 13 + 40930827 40930849 AGGCgAGTTT aag cAGCTTGTCC No 
CASP1 11 ― 104411147 104411166 AGACATGCAT   ATGCATGCAc No 
CASP10 2 + 201755017 201755041 AAACTTGCTg gttta AAtCTTGgCT No 
CASP6 4 ― 110838081 110838104 AGGCAAGGAG tttg AGACAAGTCT No 
CAV1 7 + 115952057 115952087 GCCCAAGCAC cccagcgcggg AGAaACGTTC Yes 
CCNG1 5 + 162797510 162797529 GcACAAGCCC   AGGCTAGTCC Yes 
CCNK 14 + 99020378 99020399 AAACTAGCTT gc AGACATGCTg Yes 
CD82 11 + 44542897 44542921 AGGCAAGCTG gggca GctCAAGCCT Yes 
CDC25C 5 ― 137695540 137695570 GGGCAAGTCT taccatttcca GAGCAAGCaC No 
CDKN1A_RE1 6 + 36752204 36752223 GAACATGTCC   cAACATGTTg Yes 
CDKN1A_RE2 6 + 36753091 36753110 AGACTGGGCA   TGTCTGGGCA Yes 
CHMP4C 8 + 82806745 82806782 AAACAAGCCC agtagcagcagctgctcc GAGCTTGCCC No 
COL18A1_RE1 21 + 45697015 45697034 TGACATGTGT   GAGCATGTAT No 
COL18A1_RE2 21 + 45697491 45697510 TGACATGTGT   GAGCATGTAT No 
CRYZ 1 ― 74963572 74963594 ctGCAAGTCC att AAACcTGTTT No 
CTSD_RE1 11 ― 1741923 1741942 AAGCTgGgCC   GGGCTgaCCC No 
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CTSD_RE2 11 ― 1742152 1742171 AAcCTTGgTT   tgcAAgAgGC No 
CX3CL1 16 + 55963635 55963655 GGGCATGTTC c CAGCTTGTGG No 
DDB2 11 + 47193106 47193126 GAACAAGCCC t GGGCATGTTT Yes 
DDIT4 10 + 73703380 73703399 AAACAAGTCT   TTCCTTGATC Yes 
DDR1 6 + 30962949 30962968 GAGCTGGTCC   AGGCTTATCT No 
DKK1 10 + 53741910 53741935 AGCCAAGCTT ttaatg AACCAAGTTC No 
DNMT1 19 ― 10166756 10166782 GCGCATGCGT gttccct GGGCATGGCC No 
DUSP1 5 ― 172129554 172129574 GGTCCTGCCC a GGCAAATGGG No 
DUSP5 10 + 112246487 112246507 CAACAAGCCC t TGTCTAGTGC No 
EDN2 1 ― 41720668 41720687 CTGCAAGCCC   GGGCATGCCC Yes 
EEF1A1_RE1 6 ― 74285585 74285606 GGGCAGaCCC ga GAGCATGCCC No 
EEF1A1_RE2 6 ― 74285784 74285805 AAACATGaTT ac AGGgACaTCT No 
EEF1A1_RE3 6 ― 74286408 74286431 GGACACGTag attc GGGCAAGTCC No 
EGFR 7 + 55054199 55054221 GAGCTAGaCg tcc GGGCAGcCCC No 
EPHA2 1 ― 16356670 16356692 CACCATGTTg gcc AGGCATGTCT No 
FANCC 9 ― 97121069 97121098 GGACATGTTT aaatacttga GAGCTAtTTT No 
FAS 10 + 90741046 90741065 GGACAAGCCC   tGACAAGCCa Yes 
FDXR 17 ― 70380716 70380735 GGGCAgGagC   GGGCTTGCCC Yes 
GADD45A 1 + 67925046 67925065 GAACATGTCT   AAGCATGCTg Yes 
GDF15_RE1 19 + 18357118 18357137 cAtCTTGCCC   AGACTTGTCT Yes 
GDF15_RE2 19 + 18357996 18358015 AGcCATGCCC   GGGCAAGaaC Yes 
GML 8 + 143894249 143894268 AtGCTTGCCC   AGGCATGTCC Yes 
GPX1 3 ― 49370958 49370977 GGGCcAGaCC   AGACATGCCT Yes 
HTT/HD_RE1 4 + 3044349 3044371 cGcCATGTTg gcc AGGCTGGTCT No 
HTT/HD_RE2 4 + 3061438 3061464 AtGCTTGTTC tacagaa GAGCATGTTa No 
HTT/HD_RE3 4 + 3072173 3072198 GGGCcTGCTT ccagtt AAGCTTGCTT No 
HGF 7 ― 81237693 81237712 AcACATGTaT   TTTCcTGTTT No 
HIC1 17 + 1905568 1905587 GGcgcTGCCC   TggCAcagCT Yes 
HSP90AB1 6 + 44322842 44322871 GGGAcTGTCT gggtatcgga AAGCAAGCCT Yes 
HSPA8 11 ― 122437379 122437406 GcACTAGTTC tggacctc GcGCgTGCTT Yes 
IBRDC2 6 + 18495404 18495423 AGACAGGTCC   TGACAAGCAG Yes 
IER3 6 ― 30820530 30820549 CCACATGCCT   CGACATGTGC Yes 
IGFBP3_RE1 7 ― 45923287 45923306 GGGCAAGACC   TGCCAAGCCT No 
IGFBP3_RE2 7 ― 45924206 45924226 AAACAAGCCA c CAACATGCTT No 
IRF5 7 + 128369513 128369534 AGGCATGCCa ca AGGCATGgTC No 
KRT8 12 ― 51585038 51585059 ccGCcTGCCT cc ActCcTGCCT No 
LGALS3 14 + 54673996 54674020 GGGCTTGCAA gctgg AGCCTTGTTT No 
LIF 22 ― 28971856 28971875 GGACATGTCG   GGACAGCTCC Yes 
LRDD 11 ― 794414 794441 AGGCcTGCCT gcgtgctg GGACATGTCT Yes 
MAD1L1 7 ― 2239405 2239424 ATTCAAGCTG   ATACTGAGTA Yes 
mdm2_RE1 12 + 67489008 67489027 AGTTAAGTCC   TGACTTGTCT Yes 
mdm2_RE2 12 + 67488970 67488989 GGTCAAGTTC   AGACACGTTC Yes 
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MET 7 + 116099462 116099495 GGACggacag cacgcgaggcagac AGACAcGTgC No 
MLH1 3 + 37010251 37010271 AGGCATGTAC a GCGCATGCCC Yes 
MMP2 16 + 54068958 54068977 AGACAAGCCT   GAACTTGTCT Yes 
MSH2_RE1 2 + 47483388 47483420 AGGCTAGTTT tttttttgttttc AAGTTTCCTT No 
MSH2_RE2 2 + 47483593 47483613 GAcCTAGgCg c AGGCATGCgC No 
NDRG1 8 ― 134379022 134379053 CCACATGCAC acgcacgagcgc GCACATGAAC Yes 
NLRC4 2 ― 32344455 32344474 AGACATGTTC   CTGGTAGTTT No 
NOS3 7 + 150321654 150321676 GAGCcTcCCa gcc GGGCTTGTTC No 
ODC1_RE1 2 ― 10505290 10505319 GGGCTcGCCT tggtacagac GAGCggGCCC No 
ODC1_RE2 2 ― 10506214 10506238 GGACcAGTTC caggc GGGCgAGaCC No 
P2RXL1 22 + 19714729 19714750 GAACAAGggC at GAGCTTGTCT No 
P53AIP1 11 ― 128316011 128316030 TCTCTTGCCC   GGGCTTGTCG Yes 
PCBP4_RE1 3 ― 51971563 51971583 GgtCTTGgCC c AGACTTAGCa No 
PCBP4_RE2 3 ― 51972515 51972544 GAACTTAAGA ccgaggctct GGACAAGTTG No 
PCNA 20 + 5048821 5048840 GAACAAGTCC   GGGCATaTgT Yes 
PERP 6 ― 138466900 138466919 AGGCAAGCTC   CAGCTTGTTC No 
PLAGL1 6 ― 144311857 144311876 CAACTAGACT   AGACTAGCTT No 
PLK2_RE1 5 ― 57793125 57793147 GGtCATGaTT cct tAACTTGCCT Yes 
PLK2_RE2 5 ― 57793858 57793877 AAACATGCCT   GGACTTGCCC Yes 
PLK2_RE3 5 ― 57794080 57794102 AGACATGgTg tgt AAACTAGCTT Yes 
PLK3 1 + 45038183 45038208 TAACATGCCC gggcaa AAGCGAGCGC Yes 
PML 15 + 72074709 72074736 GcGCTgGCCT ggagccag GGGCATGTCC Yes 
PMS2 7 ― 6012202 6012223 ATACTTGATT tg TTTCTTGTAA No 
PPM1J 1 ― 113048062 113048081 GAACATGCCT   GAGCAAGCCC Yes 
PRDM1 6 + 106653151 106653170 GTGCAAGTCT   GGACATGTTT Yes 
PRKAB1 12 + 118590208 118590227 GTTCTTGCCG   CGGCTTGCCT Yes 
PTEN 10 + 89613057 89613090 GAGCAAGCCC caggcagctacact GGGCATGCTC Yes 
PYCARD 16 ― 31121811 31121832 GTGCAAGCCC ag AGACAAGCAG No 
RABGGTA 14 ― 23810330 23810357 CCTCTTGTGG aacgtgca AAGCCTGTCC Yes 
RB1 13 + 47775970 47775993 GGGCGTGCCC cgac GTGCgcGCgC Yes 
RFWD2 1 ― 174445170 174445191 AGACTTGCCT gt GAACAGTCAC No 
RPS27L 15 ― 61236487 61236506 GGGCATGTAG   TGACTTGCCC Yes 
RRM2B 8 ― 103318244 103318263 tGACATGCCC   AGGCATGTCT Yes 
S100A2 1 ― 151806761 151806780 GGGCATGTgT   GGGCAcGTTC Yes 
SCARA3 8 + 27564569 27564588 GGGCAAGCCC   AGACAAGTTg Yes 
SCD 10 + 102096562 102096582 GGGCcgGTCC t GGGCTAGgCT Yes 
SCN3B_RE1 11 ― 123016908 123016927 TGGCAAGGCT   GAGCTAGTTC No 
SCN3B_RE2 11 ― 123039640 123039659 TGACTTGCTC   TGCCTTGCCT No 
SERPINB5 18 + 59294974 59294994 GAACATGTTg g AGGCcTtTTg Yes 
SERPINE1 7 + 100556945 100556964 AcACATGCCT   cAGCAAGTCC Yes 
SESN1 6 ― 109436914 109436933 GGACAAGTCT   CCACAAGTCa Yes 
SFN 1 + 27060408 27060427 GCATTAGCCC   AGACATGTCC Yes 
	 41	
SH2D1A_RE1 X + 123305989 123306014 TGGCTGGCTC agctgt CAGCTTGCTT No 
SH2D1A_RE2 X + 123305980 123305999 GGGCTGGCTC   GGCTGGCTCA No 
SH2D1A_RE3 X + 123305966 123305989 AACACTGCAC tagt GGGCTGGCTC No 
SLC38A2 12 + 45037706 45037735 AAcCATGCTg ttacacgcac CAGCTTGTCC No 
STEAP3 2 + 119719078 119719099 AGACAAGCAT ag GGACATGCTC No 
TAP1 6 ― 32929058 32929083 GGGCTTGgCC ctgccg GGACTTGCCT No 
TGFA 2 ― 70634503 70634522 GGGCAGGCCC   TGCCTAGTCT No 
TNFRSF10A 8 ― 23138086 23138105 GGGCATGTCC   GGGCAgGagg Yes 
TNFRSF10B 8 ― 22982080 22982099 GGGCATGTCC   GGGCAAGaCg Yes 
TNFRSF10C 8 + 23016747 23016766 GGGCATGTCC   GGGCAGGACG Yes 
TNFRSF10D 8 ― 23077115 23077134 GGGCATGTCT   GGGCAGGACG Yes 
TP53 17 ― 7531635 7531654 TTACTTGCCC   TTACTTGTCA Yes 
TP53INP1 8 ― 96020186 96020205 GAACTTGggg   GAACATGTTT No 
TP63 3 + 190989527 190989549 TAACTTGTTA ttg AAACATGCTC No 
TP73_RE1 1 + 3556358 3556385 GtACTTGCCg tccgggga GAACTTGCag Yes 
TP73_RE2 1 + 3556376 3556406 GAACTTGCag agtaagctgga GAGCTTGaaT Yes 
TP73_RE3 1 + 3597020 3597050 GGGCAAGCTg aggcctgcccc GGACTTGGAT Yes 
TRIAP1 12 + 119368523 119368542 CTTCATGTCC   GTGCATGCCT Yes 
TRIM22 11 + 5668357 5668376 TGACATGTCT   AGGCATGTAG Yes 
TRPM2_RE1 21 + 44595747 44595771 GGCCTTGCCT tgctc AGGCCTGCTT No 
TRPM2_RE2 21 + 44596120 44596152 GAGCAGGTCT gacctgcttccca GGGCCTGCTT No 
TRPM2_RE3 21 + 44595752 44595771 TGCCTTGCTC   AGGCCTGCTT No 
TSC2_RE1 16 + 2041179 2041198 GGGCATGGTG   GCACATGCCT No 
TSC2_RE2 16 + 2042521 2042553 AGGCTAGTCT gaaactcctgggc TGACGTGACC No 
TSC2_RE3 16 + 2052179 2052199 TAACAAGCTC g GGGCTAGCCC No 
TYRP1_1 9 + 12683326 12683349 CGCCTAGTTT gggt GAGCAGATTT No 
TYRP1_2 9 + 12683340 12683372 GAGCAGATTT gggattaattatc AGGCAGCAAT No 
TYRP1_3 9 + 12683373 12683392 CCACATGCAC   TTAACAGTTC No 
TYRP1_4 9 + 12683314 12683335 AGACCAGCCC cc CGCCTAGTTT No 
TYRP1_5 9 + 12683363 12683382 AGGCAGCAAT   CCACATGCAC No 
UBD 6 ― 29635901 29635920 AGGCATGCTC   AGTGGCGTGG No 
VCAN 5 + 82804022 82804042 AGACTTGCCA c AGACAAGTCC Yes 
VDR_RE1 12 ― 46580342 46580361 TAACTAGTTT   GAACAAGTTG No 
VDR_RE2 12 ― 46580352 46580374 AGGTTAGATG tac TAACTAGTTT No 
Table A-1: The 154 experimentally validated p53 response elements (REs) collected 
from Riley et al. [18].   
